Replies to post #1445 on Cytokinetics, Inc. (CYTK)

[H2R]

Sorry to hear that Sugarshaker,that's one terrible disease.

I do think CYTK has a good shot at improving some of the functions (especially respiratory/lungs) of ALS patients, even if, as you write, "it's extremely hard to pass a phase 3 in ALS"

I personally like Smith on Stocks' analysis:

The end point of the trial is slow vital capacity (SVC). In the earlier phase 2b BENEFIT-ALS trial this proscribed endpoint was achieved with a p-value of <0.0001 and the trial design and baseline patient characteristics of the two trials are comparable. The outcome of this trial will have a dramatic effect on the stock price. My guess is that if the stock is trading at $13 at the time of the topline release that success could catapult the stock price to $21 or perhaps much more. A disappointing outcome could drop the stock to $7. Importantly

https://smithonstocks.com/cytokinetics-reiteration-of-my-long-standing-buy-recommendation-based-on-an-extraordinary-pipeline-cytk-12-90-buy/

And CYTK also has more really interesting trials, including pivotal phase 3 trial GALACTIC-HF/ omecamtiv mecarbil / Congestive Heart Failure (CHF), which is very promising (more so that ALS in my views).

Best of luck in your investments!